Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Beinhardt, S; Al Zoairy, R; Ferenci, P; Kozbial, K; Freissmuth, C; Stern, R; Stättermayer, AF; Stauber, R; Strasser, M; Zoller, H; Watschinger, B; Schmidt, A; Trauner, M; Hofer, H; Maieron, A.
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Transpl Int. 2016; 29(9):999-1007
Doi: 10.1111/tri.12799
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Stauber Rudolf
- Trauner Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- DAA-based regimens for chronic hepatitis C infection encourage treatment of "difficult-to-treat" cohorts. This study investigated efficacy and safety of DAA-based regimens in HCV patients on dialysis or postkidney or liver/kidney transplantation. Twenty-five patients treated with DAA combinations were evaluated: 10 were on dialysis (eight: hemodialysis, two: peritoneal dialysis), eight were kidney transplant recipients, and seven were liver/kidney transplant recipients. Except for one patient treated with daclatasvir ([DCV]/60 mg/QD)/simeprevir ([SMV]/150 mg/QD), the others received sofosbuvir-based regimens ([SOF];400 mg/QD) combined with SMV:eight, DCV:13 or either ledipasvir ([LDV]90 mg/QD), ribavirin ([RBV];weight based) or pegylated interferon/RBV. HCV-RNA was determined by Abbott RealTime (LLOQ]:12 IU/ml) or Roche AmpliPrep/COBAS TaqMan assay (LLOQ:15 IU/ml); treatment response evaluated every 4 weeks, at the end of treatment, and 4 and 12 weeks thereafter. Twenty-four (96%) patients achieved SVR 12/24 (ITT-analysis). Mean treatment duration was 15.1 ± 5.1 weeks (±SD), and two patients terminated prematurely - both reached SVR12. Six patients were hospitalized due to complications of underlying disease. One patient achieved SVR24 but was re-infected (week 27). Kidney function remained stable; serum creatinine increased in only one patient - SOF was reduced to 400 mg/48 h. Treatment with DAA combinations in renally impaired HCV patients is highly effective and well tolerated. These findings call for further controlled trials and data from real-life cohorts. © 2016 Steunstichting ESOT.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antiviral Agents - therapeutic use
- Benzimidazoles - therapeutic use
- Cohort Studies -
- Drug Therapy, Combination -
- Female -
- Fluorenes - therapeutic use
- Hepacivirus - genetics
- Hepatitis C, Chronic - drug therapy
- Hepatitis C, Chronic - surgery
- Humans -
- Imidazoles - therapeutic use
- Immunosuppressive Agents - therapeutic use
- Kidney - pathology
- Kidney Function Tests -
- Kidney Transplantation -
- Liver - pathology
- Liver Transplantation -
- Male -
- Middle Aged -
- Postoperative Period -
- Preoperative Period -
- RNA, Viral - genetics
- Renal Dialysis -
- Renal Insufficiency - surgery
- Simeprevir - therapeutic use
- Sofosbuvir - therapeutic use
- Find related publications in this database (Keywords)
- chronic kidney disease (CKD)
- dialysis
- direct-acting antivirals (DAA)
- end-stage renal disease (ESRD)
- IFN-free
- renal transplantation